PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32741259-7 2020 Camostat and bromhexine are known TMPRSS2 inhibitor drugs, hence these were used as control molecules throughout the study. camostat 0-8 transmembrane serine protease 2 Homo sapiens 34-41 33750821-4 2021 In vivo studies indicate that 8P9R or the combination of repurposed drugs (umifenovir also known as arbidol, chloroquine and camostat which is a TMPRSS2 inhibitor), simultaneously interfering with the two entry pathways of coronaviruses, can significantly suppress SARS-CoV-2 replication in hamsters and SARS-CoV in mice. camostat 125-133 transmembrane serine protease 2 Homo sapiens 145-152 33676899-0 2021 Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. camostat 0-17 transmembrane serine protease 2 Homo sapiens 52-59 33903855-0 2021 Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. camostat 34-51 transmembrane serine protease 2 Homo sapiens 16-23 33903855-4 2021 Within 48 h of admission, participants were randomly assigned in a 2:1 ratio to receive the TMPRSS2 inhibitor camostat mesilate 200 mg three times daily for 5 days or placebo. camostat 110-127 transmembrane serine protease 2 Homo sapiens 92-99 33996911-3 2021 However, while camostat and nafamostat inhibit TMPRSS2 by forming a covalent adduct, the mode of action of bromhexine remains unclear. camostat 15-23 transmembrane serine protease 2 Homo sapiens 47-54 33647240-0 2021 Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. camostat 34-51 transmembrane serine protease 2 Homo sapiens 16-23 33176395-3 2021 Camostat mesylate, an orally available well-known serine protease inhibitor, is a potent inhibitor of TMPRSS2 and has been hypothesized as a potential antiviral drug against COVID-19. camostat 0-17 transmembrane serine protease 2 Homo sapiens 102-109 33505639-2 2021 Recent studies showed that two drugs, Camostat and Nafamostat, might be repurposed to treat COVID-19 by inhibiting human TMPRSS2 required for proteolytic activation of viral spike (S) glycoprotein. camostat 38-46 transmembrane serine protease 2 Homo sapiens 121-128 32793911-0 2020 Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. camostat 0-17 transmembrane serine protease 2 Homo sapiens 52-59 32793911-2 2020 The protease inhibitor camostat mesylate inhibits SARS-CoV-2 infection of lung cells by blocking the virus-activating host cell protease TMPRSS2. camostat 23-40 transmembrane serine protease 2 Homo sapiens 137-144 32664879-9 2020 We further discussed that polymorphisms in ACE2 or TMPRSS2 could guide effective treatments (i.e., hydroxychloroquine and camostat) for COVID-19. camostat 122-130 transmembrane serine protease 2 Homo sapiens 51-58 34406858-4 2021 Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway. camostat 54-71 transmembrane serine protease 2 Homo sapiens 25-32 34787160-4 2021 Thus, four potential drugs (bromhexine, camostat, gabexate, and nafamostat) were used to explore the mechanism of binding with TMPRSS2 in this work. camostat 40-48 transmembrane serine protease 2 Homo sapiens 127-134 34787160-6 2021 Through the results of calculating binding free energy by nine methods, the binding affinity of camostat, gabexate, and nafamostat to TMPRSS2 showed great advantages compared with bromhexine, where the nafamostat was surprisingly found to present two reasonable binding conformations (forward and reverse directions). camostat 96-104 transmembrane serine protease 2 Homo sapiens 134-141 32595355-7 2020 Both binding energy results as well as crucial residues in ligand binding were also compared with a positive control TMPRSS2 inhibitor, Camostat mesylate. camostat 136-153 transmembrane serine protease 2 Homo sapiens 117-124 34692233-5 2021 Consistently, the combination of the CTPB inhibitor CA-074 methyl ester and the TMPRSS2 inhibitor Camostat reduced the viral load to 0.0078+-0.0057%. camostat 98-106 transmembrane serine protease 2 Homo sapiens 80-87 34406858-4 2021 Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway. camostat 54-71 transmembrane serine protease 2 Homo sapiens 130-137 35104687-13 2022 Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis, in the treatment of COVID-19. camostat 93-110 transmembrane serine protease 2 Homo sapiens 31-38 34100014-4 2021 Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway. camostat 54-71 transmembrane serine protease 2 Homo sapiens 25-32 34100014-4 2021 Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway. camostat 54-71 transmembrane serine protease 2 Homo sapiens 130-137 34075338-0 2021 Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach. camostat 91-108 transmembrane serine protease 2 Homo sapiens 48-55 34075338-5 2021 Hence, we have used a molecular dynamics (MD) simulated homology model of TMPRSS2 to study the inhibition mechanism of experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride (BHH) using molecular modeling techniques. camostat 151-168 transmembrane serine protease 2 Homo sapiens 74-81 35072549-5 2022 Two known TMPRSS2 inhibitors, namely camostat and nafamostat, approved drugs for the treatment of pancreatitis, are under clinical trials as potential drugs against COVID-19. camostat 37-45 transmembrane serine protease 2 Homo sapiens 10-17 35412356-5 2022 For camostat 200 mg dosed four times daily, 90% inhibition of TMPRSS2 is predicted to occur but with only about 40% viral entry inhibition. camostat 4-12 transmembrane serine protease 2 Homo sapiens 62-69